Abstract
Treatment of tuberculosis with main anti-tuberculosis drugs (OAT) includes isoniazid (INH), rifampin (RIF), ethambutanol (EMB), streptomycin (SM), and pyrazinamide (PZA). Although most Anti-Tuberculosis Drugs (OAT) are acceptable in therapy, they have potential side effects, including the side effects of hematological reactions such as anemia. This study's purpose was to compare HB levels before and after the intensive phase of Anti-Tuberculosis Drugs treatment in TB patients at Petanahan Public Health Care Center, Kebumen Regency. This was an analytic observational study with a cross-sectional design. The sample in this study was 28 people. The result showed that the average Hb level of pulmonary TB patients at Petanahan Public Health Care Center before and after the treatment were 11.05 g/dl and 11.6 g/dl, respectively. Therefore there was an effect of comparing Hb levels before and after the intensive phase of Anti-Tuberculosis Drugs treatment in pulmonary TB patients at the Petanahan Public Health Center in 2021. The increase in the average Hb levels of patients with pulmonary TB before and after the treatment was 0.55. The sig values obtained from the analysis of Hb levels before and after the treatment were a = 0.200 (p0.005) and 0.023, respectively. Due to the P value (0.023 < 0.05), Ho was rejected. It meant that there was a difference in Hb levels before and after the Intensive Phase of Anti-Tuberculosis Drugs treatment in patients with pulmonary TB at Petanahan Public Health Care Center, Kebumen Regency.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.